Home › Xellia Enters 4 Year Collaboration To Develop New Antibiotics To Combat Multi-Drug Resistant Bacteria
 

Keywords :   


Xellia Enters 4 Year Collaboration To Develop New Antibiotics To Combat Multi-Drug Resistant Bacteria

2013-02-26 05:02:00| drugdiscoveryonline Home Page

Xellia Pharmaceuticals, a fully integrated specialty pharmaceutical company focusing on the global anti-infective market, announced recently that it is developing new antibiotics effective against multi-drug resistant (MDR), Gram-negative bacteria

Tags: year develop collaboration combat

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11Registration Now Open for RadTech 2025
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Public Advisory Number 7A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Vodafone-Three merger could get green light, watchdog says
05.11Altice USA residential video RGUs down 77,000 in 3Q 2024
More »